DO-IMRT Improves Swallowing Function in Head and Neck Cancer
Dysphagia-optimized IMRT improved swallowing function, when compared to standard IMRT, in patients with head and neck cancer.
Dysphagia-optimized IMRT improved swallowing function, when compared to standard IMRT, in patients with head and neck cancer.
Oropharyngeal cancer patients who have discordant p16 and HPV status have worse prognosis than patients who have p16+/HPV+ disease, a study suggests.
Non-Hispanic White men are less likely to die from HPV-related oropharyngeal cancer, when compared with Hispanic and non-Hispanic Black men.
Reducing the radiotherapy dose and target volume to subclinical regions produced “favorable clinical outcomes,” according to researchers.
The incidence of oropharyngeal cancer in men increased 2.7% per year.
Under a status quo scenario based on current levels of HPV vaccination, 792,000 OPC cases in men would be prevented by the year 2100.
The 2-year progression-free survival rate exceeded 90% for all treatment arms.
Findings suggest a need for tailored treatment in oropharyngeal squamous cell carcinoma.
Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).
This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).